{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:17:35Z","timestamp":1782508655470,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.otc.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T01:21:54Z","timestamp":1655947314000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gender-Affirming Hormone Therapy"],"prefix":"10.1016","volume":"55","author":[{"given":"C. Michael","family":"Haben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2016.303578","article-title":"Transgender population size in the united states: a meta- regression of population-based probability samples","volume":"107","author":"Meerwijk","year":"2017","journal-title":"Am J Public Health"},{"key":"10.1016\/j.otc.2022.04.002_bib2","unstructured":"Available at: https:\/\/www1.nyc.gov\/assets\/cchr\/downloads\/pdf\/publications\/GenderID_Card2015.pdf. Accessed February 14, 2022."},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/trgh.2019.0070","article-title":"Changing demographics in transgender individuals seeking hormonal therapy: are trans women more common than trans men?","volume":"5","author":"Leinung","year":"2020","journal-title":"Transgend Health"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.21037\/tau.2019.04.09","article-title":"Demographic and temporal trends in transgender identities and gender confirming surgery","volume":"8","author":"Nolan","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01542614","article-title":"Interim report of the DSM-IV subcommittee on gender identity disorders","volume":"20","author":"Bradley","year":"1991","journal-title":"Arch Sex Behav"},{"key":"10.1016\/j.otc.2022.04.002_bib6","unstructured":"Available at: https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Practice\/DSM\/APA_DSM-5-Gender- Dysphoria.pdf. Accessed February 14, 2022."},{"key":"10.1016\/j.otc.2022.04.002_bib7","series-title":"The report of the 2015\u00a0U.S. transgender survey","author":"James","year":"2016"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/andr.13052","article-title":"Health and health care access in the US transgender population health (TransPop) survey","volume":"9","author":"Feldman","year":"2021","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib9","doi-asserted-by":"crossref","first-page":"100448","DOI":"10.1016\/j.esxm.2021.100448","article-title":"How early in life do transgender adults begin to experience gender dysphoria? why this matters for patients, providers, and for our healthcare system","volume":"9","author":"Zaliznyak","year":"2021","journal-title":"Sex Med"},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib10","doi-asserted-by":"crossref","first-page":"e20193006","DOI":"10.1542\/peds.2019-3006","article-title":"Body dissatisfaction and mental health outcomes of youth on gender-affirming hormone therapy","volume":"145","author":"Kuper","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.otc.2022.04.002_bib11","article-title":"Approach to the patient: pharmacological management of trans and gender diverse adolescents","author":"O'Connell","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.otc.2022.04.002_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jbmr.4262","article-title":"Development of hip bone geometry during gender-affirming hormone therapy in transgender adolescents resembles that of the experienced gender when pubertal suspension is started in early puberty","volume":"36","author":"van der Loos","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib13","first-page":"55","article-title":"Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals","volume":"2","author":"Weinand","year":"2015","journal-title":"J\u00a0Clin Transl Endocrinol"},{"key":"10.1016\/j.otc.2022.04.002_bib14","doi-asserted-by":"crossref","first-page":"717766","DOI":"10.3389\/fendo.2021.717766","article-title":"Short-term effects of gender-affirming hormone therapy on dysphoria and quality of life in transgender individuals: a prospective controlled study","volume":"12","author":"Foster Skewis","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/EJE-19-0463","article-title":"Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria","volume":"182","author":"Meyer","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.otc.2022.04.002_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15532739.2011.700873","article-title":"Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7","volume":"13","author":"Coleman","year":"2011","journal-title":"Int J Transgend"},{"issue":"1","key":"10.1016\/j.otc.2022.04.002_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.psc.2016.10.012","article-title":"Past and future challenges associated with standards of care for gender transitioning clients","volume":"40","author":"Fraser","year":"2017","journal-title":"Psychiatr Clin North Am"},{"issue":"11","key":"10.1016\/j.otc.2022.04.002_bib18","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender- dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib19","doi-asserted-by":"crossref","first-page":"e048943","DOI":"10.1136\/bmjopen-2021-048943","article-title":"International clinical practice guidelines for gender minority\/trans people: systematic review and quality assessment","volume":"11","author":"Dahlen","year":"2021","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5694\/mja17.01044","article-title":"Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents","volume":"209","author":"Telfer","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/j.otc.2022.04.002_bib21","author":"Chen"},{"issue":"11","key":"10.1016\/j.otc.2022.04.002_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamapediatrics.2021.2068","article-title":"Access to care for transgender and nonbinary youth: ponder this, innumerable barriers exist","volume":"175","author":"Inwards-Breland","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.otc.2022.04.002_bib23","first-page":"CD013138","article-title":"Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women","volume":"11","author":"Haupt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.otc.2022.04.002_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jalm\/jfaa028","article-title":"Reproductive endocrinology reference intervals for transgender women on stable hormone therapy","volume":"6","author":"Greene","year":"2021","journal-title":"J\u00a0Appl Lab Med"},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/jc.2018-01777","article-title":"Progesterone is important for transgender women's therapy-applying evidence for the benefits of progesterone in ciswomen","volume":"104","author":"Prior","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17446651.2020.1825075","article-title":"Endocrine treatment of transgender individuals: current guidelines and strategies","volume":"15","author":"Prince","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.otc.2022.04.002_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bjsports-2020-103106","article-title":"How does hormone transition in transgender women change body composition, muscle strength and haemoglobin? Systematic review with a focus on the implications for sport participation","volume":"55","author":"Harper","year":"2021","journal-title":"BJSM Online"},{"key":"10.1016\/j.otc.2022.04.002_bib28","doi-asserted-by":"crossref","first-page":"621075","DOI":"10.3389\/fpsyt.2021.621075","article-title":"Physical and sociodemographic features associated with quality of life among transgender women and men using gender-affirming hormone therapy","volume":"12","author":"Silva","year":"2021","journal-title":"Front Psychiatr"},{"issue":"5","key":"10.1016\/j.otc.2022.04.002_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/iju.14499","article-title":"What is the most anticipated change induced by treatment using gender-affirming hormones in individuals with gender incongruence?","volume":"28","author":"Masumori","year":"2021","journal-title":"Int J Urol"},{"issue":"8","key":"10.1016\/j.otc.2022.04.002_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.NAJ.0000577420.37447.fd","article-title":"First Oral Testosterone Product Now Available","volume":"119","author":"Aschenbrenner","year":"2019","journal-title":"Am J Nurs"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21037\/tau.2016.09.04","article-title":"Hormone therapy for transgender patients","volume":"5","author":"Unger","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.otc.2022.04.002_bib32","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1038\/s41598-021-82134-2","article-title":"Testosterone therapy masculinizes speech and gender presentation in transgender men","volume":"11","author":"Hodges-Simeon","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/PRS.0000000000002171","article-title":"Facial feminization: systematic review of the literature","volume":"137","author":"Morrison","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/PRS.0000000000007786","article-title":"Perioperative transgender hormone management: avoiding venous thromboembolism and other complications","volume":"147","author":"Hontscharuk","year":"2021","journal-title":"Plast Reconstr Surg"},{"issue":"7","key":"10.1016\/j.otc.2022.04.002_bib35","first-page":"1280","article-title":"Risk for venous thromboembolism in transgender patients undergoing cross-sex hormone treatment: a systematic review","volume":"18","author":"Kotamarti","year":"2021","journal-title":"J\u00a0Sex Med"},{"issue":"9","key":"10.1016\/j.otc.2022.04.002_bib36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0026-0495(89)90233-3","article-title":"Mortality and morbidity in transsexual patients with cross-gender hormone treatment","volume":"38","author":"Asscheman","year":"1989","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9382","key":"10.1016\/j.otc.2022.04.002_bib38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"issue":"6771","key":"10.1016\/j.otc.2022.04.002_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/bmj.302.6771.269","article-title":"Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery","volume":"302","author":"Robinson","year":"1991","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0029-7844(96)00513-3","article-title":"Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol","volume":"89","author":"Price","year":"1997","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11154-018-9449-0","article-title":"Endocrine treatment of aging transgender people","volume":"19","author":"Gooren","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/lgbt.2019.0306","article-title":"Medicare prescription drug plan coverage of hormone therapies used by transgender individuals","volume":"7","author":"Solotke","year":"2020","journal-title":"LGBT health"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eprac.2021.03.010","article-title":"Minimizing venous thromboembolism in feminizing hormone therapy: applying lessons from cisgender women and previous data","volume":"27","author":"Zucker","year":"2021","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0031-1281486","article-title":"Aesthetic and functional male to female genital and perineal surgery: feminizing vaginoplasty","volume":"25","author":"Reed","year":"2011","journal-title":"Semin Plast Surg"},{"issue":"5","key":"10.1016\/j.otc.2022.04.002_bib45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/PRS.0000000000002684","article-title":"Surgical outcome after penile inversion vaginoplasty: a retrospective study of 475 transgender women","volume":"138","author":"Buncamper","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1464-410X.2007.07017.x","article-title":"Feminizing genitoplasty in adult transsexuals: early and long-term surgical results","volume":"100","author":"Goddard","year":"2007","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.otc.2022.04.002_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/and.12150","article-title":"Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review","volume":"46","author":"Asscheman","year":"2014","journal-title":"Andrologia"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib48","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.24593","article-title":"Thrombotic issues in transgender medicine: a review","volume":"92","author":"Shatzel","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.otc.2022.04.002_bib49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/BF03345758","article-title":"SIAMS-ONIG Consensus on hormonal treatment in gender identity disorders","volume":"32","author":"Godano","year":"2009","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.otc.2022.04.002_bib50","doi-asserted-by":"crossref","first-page":"168e","DOI":"10.1097\/PRS.0b013e318254b4ee","article-title":"Evidence-based practices for thromboembolism prevention: summary of the ASPS Venous Thromboembolism Task Force Report","volume":"130","author":"Murphy","year":"2012","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.prs.0000475790.54231.28","article-title":"Benefits and Risks of Prophylaxis for Deep Venous Thrombosis and Pulmonary Embolus in Plastic Surgery: A Systematic Review and Meta-Analysis of Controlled Trials and Consensus Conference","volume":"137","author":"Pannucci","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.otc.2022.04.002_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/EJA.0000000000000729","article-title":"European guidelines on perioperative venous thromboembolism prophylaxis: Executive summary","volume":"35","author":"Afshari","year":"2018","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"10.1016\/j.otc.2022.04.002_bib53","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/AOG.0000000000002818","article-title":"750: perioperative pathways: enhanced recovery after surgery","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10508-006-9104-9","article-title":"Patient-reported complications and functional outcomes of male-to-female sex reassignment surgery","volume":"35","author":"Lawrence","year":"2006","journal-title":"Arch Sex Behav"},{"issue":"11","key":"10.1016\/j.otc.2022.04.002_bib55","first-page":"2190","article-title":"Testicular functions and clinical characterization of patients with gender dysphoria (GD) undergoing sex reassignment surgery (SRS)","volume":"12","author":"Schneider","year":"2015","journal-title":"J\u00a0Sex Med"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib56","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1213\/ANE.0000000000003371","article-title":"The Perioperative Care of the Transgender Patient","volume":"127","author":"Tollinche","year":"2018","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.otc.2022.04.002_bib57","first-page":"539","article-title":"Estradiol Therapy in the Perioperative Period: Implications for Transgender People Undergoing Feminizing Hormone Therapy","volume":"93","author":"Nolan","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib58","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1210\/jc.2018-02138","article-title":"Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen","volume":"104","author":"van Velzen","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/HJH.0000000000002632","article-title":"Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review","volume":"39","author":"Connelly","year":"2021","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/imj.14839","article-title":"Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals","volume":"51","author":"Nolan","year":"2021","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.otc.2022.04.002_bib61","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","article-title":"Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years","volume":"106","author":"Madsen","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.otc.2022.04.002_bib62","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.amjmed.2021.02.031","article-title":"Assessment of cardiovascular risk in transgender patients presenting for gender-affirming care","volume":"134","author":"Denby","year":"2021","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.otc.2022.04.002_bib63","doi-asserted-by":"crossref","first-page":"E423","DOI":"10.1002\/lary.28842","article-title":"Neonatal ear molding","volume":"131","author":"Gulati","year":"2021","journal-title":"Laryngoscope"},{"issue":"9","key":"10.1016\/j.otc.2022.04.002_bib64","first-page":"1662","article-title":"Longitudinal changes in liver enzyme levels among transgender people receiving gender affirming hormone therapy","volume":"18","author":"Hashemi","year":"2021","journal-title":"J\u00a0Sex Med"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666522000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666522000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T08:23:52Z","timestamp":1672388632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666522000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0030666522000366"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2022.04.002","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gender-Affirming Hormone Therapy","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}